ARTHUR-D.-LITTLE
18.11.2021 12:44:05 CET | Business Wire | Press release
Arthur D. Little (ADL) today released ‘The insight: how Europe’s private equity industry is anchoring long-term investors’, a new report based on a survey conducted in partnership with Invest Europe, the association that represents Europe’s private equity, venture capital and infrastructure sectors and their investors. The report shows that, despite the ongoing impact of COVID-19 on business and society, private equity investment levels reached a new record high in the first half of 2021. This is a dramatic bounce-back compared to the same period last year, with fund managers and investors evidently facing the future with greater confidence.
The report also highlights that far from adopting a return to ‘business as usual’ approach, private equity is now concentrating on new priorities, with the greatest shift being an increased focus on environmental, social and governance (ESG) issues. For example, 95.5% of general partners (GPs) said they intended to increase their focus on ESG over the coming year, and 86% are planning to concentrate more on diversity and inclusion. In addition, 45.9% of investors expecting to increase allocations to environmental/social impact funds over the coming 12 months.
While cost reduction was the top prioritized initiative for GPs last year, it dropped to sixth place in this year’s survey. Instead, the leading priority was digitalization as managers invest in technology to add value. In particular, the pandemic has spurred a mass roll-out of new technology solutions at portfolio companies to enable flexible ways of working for staff and build more innovative platforms for improved collaboration.
As the general outlook improves, the survey indicates a healthy future for private equity. More than 50% of fund managers see stronger investment opportunities in the coming year, and almost 60% of investors expect increased allocations to private equity over the coming three years.
Jonas Fagerlund, co-author of the report and Lead Partner in ADL’s Global Private Equity practice , comments: “The message that comes through loud and clear through this report and the survey it is based on is that European private equity is adaptable, resilient and innovative, and looking forward to the future. The industry has come through a challenging period for the global economy with higher-than-ever levels of investment, robust fundraising, and an improving outlook for divestments.”
Guillaume Picq, co-author of the report and Partner in ADL’s Private Equity practice , adds, “While GPs are looking to deploy new value creation strategies, more investors want to commit to funds that deliver tangible benefits for people and the planet alongside investment returns. ESG is a trend that Europe is leading, and that the European private equity industry is committed to supporting.”
To download a copy of the report please visit: www.adl.com/PrivateEquityAnchor
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118005726/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
